Retatrutide 10mg peptide High purity Factory Supply Freeze dried powder
2 Inquiries
232544-43-3
Pharmaceutical Grade
99%
China
KZY
10mg/vial
2026-09-03
Retatrutide,Tirzepatide,Samaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
RT20
CAS No.:232544-43-3
Categories:
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Samaglutide
-
Location:
Room 205, Sanyuanli Avenue, Baiyun District, Guangzhou City
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2026
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
Canada
RT20
200 MG Aug 13, 2026
Australia
Rt20
10 G Jul 28, 2026 Post an enquiry for this product